Prediction model for hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitors

被引:21
|
作者
Choi, Yong Jun [1 ]
Kim, Taehee [1 ]
Kim, Eun Young [1 ]
Lee, Sang Hoon [1 ]
Kwon, Do Sun [1 ]
Chang, Yoon Soo [1 ]
机构
[1] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea
基金
新加坡国家研究基金会;
关键词
Hyperprogressive disease; NSCLC; PD-L1; inhibitor; prognosis; BONE-MARROW; SURVIVAL; NIVOLUMAB; DOCETAXEL; BLOCKADE;
D O I
10.1111/1759-7714.13594
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Hyperprogressive disease (HPD) is a paradoxical acceleration of tumor growth after immune checkpoint inhibitor (ICI) treatment. This study aimed to identify the risk factors and to present a predictive model for HPD in patients treated with ICIs. Methods A total of 78 non-small cell lung cancer (NSCLC) cases, treated with at least two cycles of ICIs who underwent computed tomography (CT) for response assessment were recruited into the study from January 2016 to August 2019. HPD was defined by the following criteria: (i) time-to-treatment failure <2 months; (ii) a 50% increase in the sum of target lesion diameters; (iii) new development of at least two lesions in an already involved organ; (iv) appearance of a new organ lesion; and (v) a decrease in ECOG PS 2. Results Of the 78 total patients, 15 (19.2%) had HPD. The risk factors of HPD were age; primary lesion size; and metastases in the contralateral lung, pleura, liver, and bone in multivariable logistic regression (odds ratio [OR]; 0.9038, 1.6619, 28.5913, 23.8264, 14.5711, and 20.1533, respectively, allP-values < 0.05). By using these risk factors, we developed a prediction model for HPD and the area under the receiver operating characteristic curve of the model was 0.9556 (95% confidence interval [CI]: 0.9133-0.9978). Conclusions HPD is relatively common and associated with a grave clinical outcome, requiring a careful monitoring in lung cancer patients treated with ICIs. Moreover, risk factors such as age, size of tumor and number of various metastatic lesions should be taken into consideration before ICI administration. Key pointsSignificant findings of the study Age, primary lesion size, and number of metastases are risk factors of HPD. HPD is strongly associated with poor prognosis. HPD during ICI use needs comprehensive monitoring. What this study adds This is the first study to develop a prediction model. The area under the curve of the prediction model for HPD was 0.9556.
引用
收藏
页码:2793 / 2803
页数:11
相关论文
共 50 条
  • [41] Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series
    Kanazu, Masaki
    Edahiro, Ryuya
    Krebe, Hiroyuki
    Nishida, Kohei
    Ishijima, Mikako
    Uenami, Takeshi
    Akazawa, Yuki
    Yano, Yukihiro
    Yamaguchi, Toshihiko
    Mori, Masahide
    THORACIC CANCER, 2018, 9 (12) : 1782 - 1787
  • [42] Hyperprogressive disease in patients with non-small cell lung cancer on immunotherapy
    Kurman, Jonathan S.
    Murgu, Septimiu D.
    JOURNAL OF THORACIC DISEASE, 2018, 10 (02) : 1124 - 1128
  • [43] Survival of patients with non-small cell lung cancer having leptomeningeal metastases treated with immune checkpoint inhibitors
    Hendriks, Lizza E. L.
    Bootsma, Gerben
    Mourlanette, Jean
    Henon, Clemence
    Mezquita, Laura
    Ferrara, Roberto
    Audigier-Valette, Clarisse
    Mazieres, Julien
    Lefebvre, Corentin
    Duchemann, Boris
    Cousin, Sophie
    le Pechoux, Cecile
    Botticella, Angela
    De Ruysscher, Dirk
    Dingemans, Anne-Marie C.
    Besse, Benjamin
    EUROPEAN JOURNAL OF CANCER, 2019, 116 : 182 - 189
  • [44] The Impact of Inflammatory Serum Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
    Cipriano, E.
    Magalhaes, H.
    Estevinho, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S255 - S255
  • [45] Restricted mean survival time in advanced non-small cell lung cancer treated with immune checkpoint inhibitors
    Di Spazio, L.
    Cancanelli, L.
    Rivano, M.
    Chiumente, M.
    Mengato, D.
    Messori, A.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2021, 25 (04) : 1881 - 1889
  • [46] Prediction performance comparison of biomarkers for response to immune checkpoint inhibitors in advanced non-small cell lung cancer
    Zhao, Jie
    Zhuang, Wei
    Sun, Boyang
    Bai, Hua
    Wang, Zhijie
    Zhong, Jia
    Wan, Rui
    Liu, Lihui
    Duan, Jianchun
    Wang, Jie
    THORACIC CANCER, 2024, 15 (13) : 1050 - 1059
  • [47] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
    Wei Yuxi
    Xu Yan
    Wang Mengzhao
    中华医学杂志英文版, 2023, 136 (13)
  • [48] Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer
    Itsuki Yuasa
    Masatsugu Hamaji
    Hiroaki Ozasa
    Yuichi Sakamori
    Hironori Yoshida
    Yojiro Yutaka
    Toshi Menju
    Toyohiro Hirai
    Hiroshi Date
    General Thoracic and Cardiovascular Surgery, 2023, 71 : 534 - 541
  • [49] Blood Biomarkers of Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Alfranca, Yolanda Lage
    Garcia, Maria Eugenia Olmedo
    Rueda, Ana Gomez
    Ballesteros, Pablo Alvarez
    Rodriguez, Diana Rosero
    Velasco, Marisa Torres
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (11)
  • [50] Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
    Zhou, Kexun
    Li, Shuo
    Zhao, Yi
    Cheng, Ke
    FRONTIERS IN IMMUNOLOGY, 2023, 14